Last $92.29 USD
Change Today +0.64 / 0.70%
Volume 2.1M
NVS On Other Exchanges
Symbol
Exchange
SIX Swiss Ex
Xetra
New York
OTC US
Mexico
SIX Swiss Ex
Frankfurt
As of 8:04 PM 12/17/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Lichtstrasse 35

Basel, 4056

Switzerland

Phone: 41 61 324 11 11

Fax:

Additional patents claiming certain innovative forms or uses of these products, in particular Reclast/Aclasta, have been granted in some countries including the U.S. and Europe. Patent litigations are ongoing in the U.S., Europe and elsewhere. Femara. Patent protection for the active ingredient in Femara expired in the U.S., in major European markets, and in Japan. Data exclusivity in Japan expires in 2014. Generic versions of Femara are available now in all major markets with the exception of Japan. Jakavi: Basic compound patent protection (including SPC) for ruxolitinib, the active ingredient in Jakavi, expires in 2027 in Europe. Novartis licensed ruxolitinib from Incyte Corporation for development and commercialization outside the U.S. Primary Care Primary Care Medicines Exforge/Exforge HCT: The patent covering the Exforge product (the combination of amlodipine besylate and valsartan) would expire in 2019 in the U.S. and 2021 (including term extension) in Europe and has been challenged in both the U.S. and Europe. In the U.S., under a license agreement with a generics manufacturer, the product is expected to face generic competition prior to patent expiry. The company has regulatory exclusivity for the data generated for Exforge in Europe until 2017 and in Japan until 2014. Generic manufacturers may attempt to circumvent this regulatory exclusivity and seek to gain approval of a combination valsartan-amlodipine product in Europe before 2017. The patent covering the Exforge HCT product (the combination of amlodipine besylate, hydrochlorothiazide and valsartan) would expire in 2023 and has been challenged in the U.S. Galvus and Eucreas: Patent protection for vildagliptin, the active ingredient of Galvus, and the patented active ingredient in Eucreas, is estimated to expire, with extensions, in 2019 to 2024. Xolair. Patent protection for the active ingredient in Xolair would expire in 2018 in the U.S., in 2017 in Europe and in Japan (if the patent term extension pending there is granted). Arcapta/Onbrez. Patent protection for the active ingredient of Onbrez (Arcapta in the U.S.) is expected to expire in 2025 in the U.S. (including patent term extension), in 2024 in Europe, and in 2020 in various other markets. Tekturna/Rasilez and combination products: Patent protection for aliskiren, the active ingredient of Tekturna/Rasilez, and various single-pill combination products, would expire in 2018 in the U.S. (not including pediatric extension) and between 2015 and 2020 in other markets. Seebri: There is no patent protection on glycopyrronium bromide, the active ingredient in Seebri. A number of patents covering the formulations, commercial product and uses of this product expire by 2025. In addition, Seebri is entitled to regulatory exclusivity for the data generated for approval until 2022 in Europe, and until 2020 in Japan. Ultibro: Ultibro is a product which combines indacaterol, the active ingredient in Arcapta/Onbrez, with glycopyrronium bromide, the active ingredient in Seebri. Patent protection for indacaterol is expected to expire in 2025 in the U.S. (including patent term extension), in 2024 in Europe (including patent term extensions), in 2025 in Japan and in 2020 in various other markets. There is no compound patent protection on glycopyrronium, but there are patents and patent applications for the dry powder formulation technology that apply to both glycopyrronium and fixed-dose combination indacaterol/glycopyrronium products. In addition, there are patents and patent applications for the combination of indacaterol and glycopyrronium that are due to expire in 2025 (excluding extensions in some countries). Established Medicines Voltaren/Cataflam: Patent protection for the active ingredient in Voltaren has expired worldwide. Ritalin LA/Focalin XR: There is no patent protection for the active ingredient in Ritalin or Focalin. A number of patents covering the formulation will expire in 2015 and 2019. Several generic manufacturers have filed applications to market generic versions of Ritalin LA and Focalin XR in the U.S. Litigation against several generic manufacturers was ini

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVS:US $92.29 USD +0.64

NVS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Gilead Sciences Inc $102.40 USD +1.94
Merck & Co Inc $57.63 USD +0.83
Pfizer Inc $31.12 USD +0.45
Sanofi €74.10 EUR +0.62
Procter & Gamble Co/The $90.70 USD +1.34
View Industry Companies
 

Industry Analysis

NVS

Industry Average

Valuation NVS Industry Range
Price/Earnings 22.6x
Price/Sales 3.8x
Price/Book 3.1x
Price/Cash Flow 23.4x
TEV/Sales 3.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVARTIS AG-SPONSORED ADR, please visit www.novartis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.